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the public sector. This might include STD treatment, for
example. If the local or provincial government is paying for a
service, it has the right to ensure that the service is of
acceptable standard? Other options include making STD drugs
or STD syndrome packets available to the private sector at state
tender prices. There is always a risk of abuse, but with correct
organisation and auditing, abuse could be minimised.
Education
Education of doctors and other health workers needs to start
with the undergraduate curriculum. Education needs to
continue through specialist and postgraduate training, and also
to be complemented by a programme of continuing medical
education thereafter. Today's health worker needs to
understand the value of evidence-based medicine, standard
treatment guidelines, and structured approaches to care.
CONCLUSION
STD control must remain a high priority for South Africa.
Achieving control is unlikely if the public sector acts alone.!'
Many patients seek care in the private medical sector and an
effective partnership between it and the public sector needs to
be forged. While quality of services can be assessed locally, it
seems likely that effective change will only occur within a
framework of legislation, financial incentives and continuing
education.
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CORTICAL LENS OPACITIES IN THE
YOUNG PATIENT - AN
INDICATION FOR A LIPOGRAM?
D Meyer, F J Maritz, P H Liebenberg, D P Parkin, L J Burgess
Aim. To determine the characteristics and prevalence of
lenticular opacification in patients·with underlying
dyslipidaemia.
Methods. Eighty patients of both genders and all ages
(18 - 90 years) were enrolled in the trial if they met the
inclusion criteria for dyslipidaemia:
Patients were included if their fasting serum cholesterol
and triglyceride concentrations were> 5.2 mmol/l and
> 2.3 mmol/l, respectively, when measured on three
separate occasions over a I-month period.
Patients were excluded if they suffered from any
condition known to cause or predispose them to elevated
lipid levels or lenticular opacification. Lenticular changes
were assessed by means of a slit-lamp through the fully
dilated pupil and other physical signs were documented
subsequent to thorough physical evaluation.
Results. In addition to the classic clinic signs of
dyslipidaemia, 31% of patients had cortical lens opacities.
Cortical opacities were twice as prevalent as Achilles
tendon thickening (16.3%) in our study, the second most
prevalent sign of elevated lipid levels. In the subgroup of
patients aged under 50 years, 55% had lenticular opacities,
predominantly cortical (80%).
Conclusions. Cortical lens opacification was the most
prevalent sign of dyslipidaemia and it occurred at a
relatively young age in our trial population in those
patients who were affected. Cortical lenticular opacification
should be regarded as an indication for blood lipid profile
evaluation.
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Lens opacification' and cardiovascular disease' are two of the
main causes of morbidity worldwide. Lens opacity, manifesting
as cataract, is responsible for an estimated 40% of the 42 million
cases of blindness in the world.' Heart disease, on the other
hand, is the single greatest cause of death in developed
countries.' The relationship between cholesterol and
cardiovascular heart disease is well documented.5-'O The
relationship between cholesterol and lens opacity is, however,
far less well appreciated.
Issues relating to drug safety and inherited defects in
enzymes mediating cholesterol metabolism have brought
renewed attention to a possible interrelationship between lipid
metabolism and cataract induction in humans. The lens is
unique in that it contains a relative abundance of cholesterol in
the fibre cell plasma membrane ll and furnishes its needs for the
latter by on-site biosynthesis." It has been shown that
inhibition of cholesterol synthesis in the lens leads to cataract
formation in humans. l1
The Smith-Lemli-Opitz syndrome,Ut5 mevalonic aciduria"
and cerebrotendinous xanthamathosis17·18 are inherited
disorders of cholesterol metabolism and affected patients may
present with lens opacities. Triparanol, a hypolipidaemic agent
that inhibits cholesterol biosynthesis, was withdrawn from
clinical use because of its propensity to induce cataract
formation in humans.19,2l1 The very widely used vastatin class of
hypolipidaemic medicines are potent inhibitors of cholesterol
biosynthesis and are able to lower serum lipid concentration
effectively.21,22 Although high ocular safety in older patients over
periods of up to 5 years has been reported,23-29 it is still not clear
whether these agents have the potential to be cataractogenic,
particularly in younger patients and over longer periods. The
vastatins have been reported to lower mortality effectively in
dyslipidaemic patients suffering from heart disease.JO.34
In order to assess the prevalence of lenticular opacities in
patients with dyslipidaemia (raised serum cholesterol and
triglycerides), a group of 80 dyslipidaemic patients were
subjected to general physical examination and an ophthalmic
eXamination of the fully dilated eye.
METHODS
In order to obtain a study group with maximum homogeneity
only patients meeting the following inclusion criteria were
enrolled: (i) male or female (18 - 90 years of age); (ii) high
serum total cholesterol (> 5.2 mmol/l); (iii) low high-density
lipoprotein (HDL) cholesterol « 1.8 mmo1/1); and (iv) high
triglycerides (> 2.3 mmol/l).
EXclusion criteria were: (i) pregnant or lactating women;
(ii) severe hypertension (diastolic blood pressure (BP)
> 115 mmHg); (iiz) history of cardiovascular disease;
(iv) diabetes mellitus (fasting blood glucose> 7.8 mmo1/1);
(v) hypothyroidism, defined as thyroid-stimulating hormone
(TSH) > 7.5 mU 11; (vi) any malignant tumour; (vii) significant
renal impairment (serum creatinine> 170 f.Ill1ol/l); (viii) history
of pancreatitis; (ix) patient with gallbladder disease, including
cholelithiasis; (x) history of gastro-intestinal disease; and
(xi) HN antibody-positive.
Fasting blood samples were obtained from each individual
on three occasions over a period of 4 weeks. Patients were only
included in the study if their lipid variables adhered to the
inclusion criteria on each of the three visits.
All classic physical signs of abnormal lipid variables were
documented, namely: (i) xanthomas (on the Achilles tendon,
hands, elbows or knees); (ii) palmar yellow striae;
(iii) xanthelasma; and (iv) corneal arcus.
Lenticular opacities were classified as being cortical, nuclear
or subcapsular on the basis of the characteristics and grading
as indicated below:
1. Cortical opacities: (i) water clefts, vacuoles, and flakes -
none, few, moderate, or many; (ii) wedges and spokes -
involving 1,2, 3 or 4 quadrants; and (iii) maximal inward
extension - minimal, moderate or advanced.
2. Nuclear opacities: (z) tissue discoloration - normal
colour, pale yellow, yellow, dark yellow or brown.
3. Subcapsular opacities: (I) posterior capsule involvement-
graded 1 - 4; and (il) anterior capsule involvement - graded 1 - 4.
A specialist physician and an ophthalmologist examined all
the patients.
RESULTS
Eighty patients were analysed and Table I reflects their
demographic data.
Table I. Demographic data
Variable Mean Standard deviation
Age (yrs) 53.9 ± 11.8
Blood pressure (mmHg)
Systolic 134 ± 18
Diastolic 84 ±9
Body mass index (kg/m') 28.29 ±4.82
umber (%)
Race
Mixed race 15 (18.8)
Caucasian 65 (81.3)
Gender
Male 48 (60)
Female 32 (40)
Smokers
Present 23 (27.5)
Past 34 (42.5)
Never 23 (27.5)
Alcohol consumer 55 (68.8)
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54.7 ± 14.8
140.0 ± 21.81
86.1 ± 9.83
27.81 ±4.84
7.91 ± 2.00
5.11 ± 1.46
1.14 ± 0.31
2.89 ± 1.02
3.98 ± 1.25
Opacity
(mean (± SD»
55.3 ± 10.9
135.6 ± 21.19
84.4 ± 10.03
28.55 ± 4.84
7.3 ± 2.01
5.05 ± 1.54
1.16 ± 0.39
2.64 ± 1.89
3.64 ± 0.91
Normal
(mean (± SD»Variable
Age (yrs)
Blood pressure (mmHg)
Systolic
Diastolic
Body mass index (kg/m2)
Total cholesterol (mmol/I)
LDL cholesterol
HDL cholesterol
Triglycerides
Uric acid (mmol/l)
Table 11. Comparison of subgroup with normal lenses (61%) and
the subgroup with lenticular opacities (39%)
Beaver Dam Eye Study (BDES),36 and consequently data for
comparison are not available. In the 40 - 50-year age group the
prevalence of lenticular opacity in our patients was 50%
compared with 4.7% in the BES and 8.3 in the BDES.
Differences in the older age groups were not prominent (Table ill,
Fig. 3).HDL cholesterolTriglycerideLDL cholesterolTotal serum
cholesterol
81==~~-------;::===========::;l
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Most of the study group patients were male, Caucasian and
smokers. Most patients (68.8%) admitted to regular alcohol
consumption. The mean systolic and diastolic BP data,
134 mm Hg (standard deviation (SD) 18 mmHg) and 84 mmHg
(SD 9 mmHg), respectively, fell within the normal range for
age. The body mass index (BMI) of the group was significantly
greater than the norm, i.e. 28.89 kg/m2 (SD 4.82 kg/m2).
Fig. 1 depicts the serum lipid variables. Patients were
included in the study only if total serum cholesterol was
> 5.2 mmol/l when measured on three separate occasions over
a 4-week period, and low-density lipoprotein (LDL) and HDL
were uniformly> 2.3 mmol/l and < 1.8 mmol/l, respectively.
Fig. 1. Serum lipid parameters of the study group (N = 80) compared
with the upper limit of normal (mmolj/). Table Ill. Age distribution of patients with opacities compared
with other population-based studies
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Age group Percentage of opacities
(yrs) Study group BES"
30 - 40 33.33 N/A
40 - 50 50.00 4.7
50 - 60 18.51 24.5
60 - 70 33.33 57.5
70 - 80 66.67 85.9
80+ 33.33 98.3
BES =Barbados Eye Study; SUES =Beaver Darn Eye Study; I A =not available.
Normal
62%
The prevalence of lenticular opacities divided the study
group into two cohorts, i.e. those with normal lenses (62%) and
those with opacities (39%) (Fig. 2).
Fig. 2. Prevalence of lens opacities in the study group.
Subgroup results
Comparative analysis with regard to age, Bp, BMI, lipid index
and uric acid profile did not reveal significant differences
between the two subgroups (Table IT).
The prevalence of lenticular opacity in dyslipidaemic
patients in the 30 - 40-year age group was 33%. This age group
was not studied in the Barbados Eye Study (BES)35 or the
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Age groups (yrs)
Fig. 3. Age distribution and percentage of patients with opacities
compared with other population-based studies.
o lateralising bias was observed in the subgroup with
lenticular opacities (Fig. 4). This is supported by the findings in
normal clinical practice, where a predilection for laterality of
age-related cataracts does not exist.
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Fig. 4. Types ofopacities compared with laterality.
DISCUSSION
Modem medicine today aspires to the early detection of
disease processes, with the aim of early intervention in an
attempt either to halt the progression or to reverse the process.
Although the classic systemic signs of dyslipidaemia are
well appreciated, i.e. xanthomas, xanthelasma, thickening of
the Achilles tendon and corneal arcus, in our study the
prevalence of one or more of the ocular signs was far greater
than that of the systemic signs - 47.3% for the former as
opposed to 23.8% for the latter.
The distribution of dyslipidaemia-related signs in our
patients was as follows: xanthelasma (7.5%), corneal arcus
(8.8%), Achilles tendon involvement (16.3%), and cortical
lenticular opacity (31.0%).
It is noteworthy that the most frequent ocular sign, cortical
lenticular opacity, occurred twice as frequently as the most
frequent systemic sign, Archilles tendon thickening (Fig. 5).
o
Percentaga
Fig. 5. Physical signs associated with dyslipidaemia.
Although a control group of patients was not evaluated
simultaneously, valid comparisons could be made between our
data and those of other population-based studies. In the BDES"
and the BES,35 40% and 41% of the patients, respectively, had
lens opacities compared with 39% in our dyslipidaemic
patients.
Fig. 6 compares the prevalence of the different
morphological subtypes of opacities in our study and in the
Fig. 6. Prevalence of the morphological types ofopacities in our
study group vs. the BDES."
BDES." It is clear that cortical opacities occurred twice as
frequently in the hyperlipidaemic group as in the normal
population, whereas nuclear opacities occurred with more than
twice tl.e frequency in the normal population.
The mean age of our patients was 53.9 ± 11.8 years, and not
surprisingly the prevalence of nuclear cataracts was relatively
low. Since nuclear degeneration correlates strongly with age
and ageing, it is more prevalent in the elderly. In contrast,
cortical lens opacities were highly prevalent in our study
group.
Patients with conditions known to induce lens opacification,
e.g. diabetes mellitus, neoplastic disease, hypothyroidism,
pancreatitis, renal failure, severe hypertension and HIV/ AIDS
complex, among others, were meticulously excluded from the
trial. Mariti" has shown that dyslipidaemic patients have a
higher risk of developing adult-onset diabetes mellitus with
advancing age than the general population. No patient in the
study group had a fasting blood glucose concentration in
excess of 7.8 mmol/l, and consequently it is highly unlikely
that hyperglycaemia contributed to the high prevalence of
cortical opacification.
Most of the patients in the BES35 were black, and the
comparative data from the trial appeared to reveal that black
people are at greater risk of developing cortical opacities than
Caucasians, and that the latter in turn are at greater risk of
developing nuclear opaciti%.
In contrast to the BES,35 most of our patients were
Caucasians (85%), the rest all being individuals of mixed race.
It is possible that capsular opacities are equally prevalent in
black and white people and our data provide sufficient
motivation for further assessment of this factor in the aetiology
of lens opacification.
Defining a cataract is difficult. Harding define it as 'An
opacification of the ocular lens sufficient to impair ocular
vision.''" We have deliberately steered away from the term
cataract because most of the lens changes were not cataracts
according to the Harding definition, but rather lenticular
opacities as described by the Lens Opacities Classification
System IT (LOCS IT).39 Tone of the observed opacities was
severe enough to cause substantial visual impairment.
It has been reported that corneal arcus represents a reliable
sign of dyslipidaemia only in patients under 50 years of age
and that 60% of patients with periocular xanthelasma are
normolipidaemic.-IO
CONCLUSIONS
Our conclusions are as follows:
1. Dyslipidaemic patients are more likely to develop cortical
opacification than the normal population.
2. Cortical lens opacification manifests at a younger age
than· does nuclear opacification.
3. It is essential that an abnormal lipid profile be diagnosed
or detected as early as possible in order to achieve the
maximum possible benefit from therapeutic intervention.
4. Cortical lens opacification in the patient younger than 50
years of age should alert the ophthalmologist to arrange for
diagnostic serum lipid assessment.
5. The young patient with dyslipidaemia should undergo
regular slit-lamp examination of the lens after full dilatation of
the pupil in order to detect early signs of lens opacification.
6. Cortical lenticular opacification should be regarded as
one of the most common, and hence reliable, clinical signs of
dyslipidaemia.
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